Skip to main content

Table 1 Baseline characteristics of patients with nonvalvular atrial fibrillation grouped by Lp(a) quartiles

From: Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study

Characteristics Lp(a) quartiles, mg/dL χ2/F/H P value
Q1(n = 4106) Q2 (n = 4075) Q3 (n = 4094) Q4 (n = 4082)
<  7.1 [7.1, 13.4) [13.4, 25.4) ≥ 25.4
Age, year 68.0 (58.0, 76.0) 69.00 (59.0, 77.0)a 70.0 (60.0, 77.0)b 70.0 (60.0, 77.0)c 44.173 <  0.001
Women, n (%) 1462 (35.6) 1522 (37.4) 1455 (35.5) 1496 (36.7) 4.033 0.258
Ethnicity, n (%)
 Other 1078 (26.3) 1130 (27.7) 1112 (27.2) 1317 (32.3)   
 Han 3028 (73.8) 2945 (72.3) 2982 (72.8) 2765 (67.7)cef 43.275 <  0.001
AF type, n (%)      53.770 <  0.001
 Paroxysmal 1441 (35.1) 1326 (32.5) 1300 (31.8)b 1320 (32.3)c   
 Persistent 282 (6.9) 183 (4.5)a 176 (4.3)b 222 (5.4)c   
 Other 2383 (58.0) 2566 (63.0)a 2618 (63.9)b 2540 (62.2)c   
Heart failure, n (%) 281 (6.8) 319 (7.8) 305 (7.5) 323 (7.9) 4.195 0.241
Hypertension, n (%) 2259 (55.0) 2320 (56.9) 2301 (56.2) 2301 (56.4) 3.235 0.357
Diabetes mellitus, n (%) 842 (20.5) 768 (18.9) 838 (20.5) 811 (19.9) 4.608 0.203
Stroke, n (%) 107 (2.6) 112 (2.8) 119 (2.9) 126 (3.1) 1.907 0.592
Vascular disease, n (%) 191 (4.7) 180 (4.4) 158 (3.9) 211 (5.2)f 8.382 0.039
CHA2DS2-VASc score 2.2 ± 1.4 2.3 ± 1.4a 2.3 ± 1.4b 2.3 ± 1.4c 7.410 <  0.001
WBC count, 109/L 6.7 (5.3, 8.2) 6.8 (5.6, 8.5)a 6.9 (5.6, 8.4)b 7.1 (5.7, 8.7)cef 74.448 <  0.001
Neutrophil count,109/L 4.0 (3.0, 5.8) 4.3 (3.2, 6.4)a 4.4 (3.3, 6.5)b 4.6 (3.4, 6.9)cef 165.592 <  0.001
Monocyte count, 109/L 0.5 (0.4,0.7) 0.6 (0.4, 0.8)a 0.6 (0.4, 0.8) 0.6 (0.4, 0.8)cef 69.262 <  0.001
Lymphocyte count, 109/L 1.8 (1.4, 2.3) 1.8 (1.4, 2.3) 1.8 (1.4, 2.3) 1.8 (1.4, 2.3) 8.581 0.035
Platelet count, 109/L 191.0 (148.0, 239.0) 200.0 (150.0, 247.0)a 201.0 (157.0, 248.0)b 210.0 (167.0, 262.0)cef 156.017 <  0.001
RDW, % 13.5 (12.9, 14.6) 13.7 (13.0, 14.8)a 13.7 (13.0, 14.8)b 13.7 (13.0, 14.8)c 50.128 <  0.001
TC, mmol/L 3.4 (2.8, 4.1) 3.5 (2.9, 4.3)a 3.6 (3.0, 4.3)bd 3.8 (3.1, 4.5)cef 225.102 <  0.001
TG, mmol/L 1.2 (0.9, 1.8) 1.2 (0.9, 1.7) 1.2 (0.9, 1.6)b 1.3 (0.9, 1.8)cef 60.614 <  0.001
LDL-C, mmol/L 2.1 (1.6, 2.7) 2.2 (1.7, 2.8)a 2.3 (1.8, 2.9)bd 2.4 (1.9, 3.0)cef 282.551 <  0.001
HDL-C, mmol/L 1.0 (0.8, 1.2) 1.0 (0.8, 1.3) 1.1 (0.9, 1.3)bd 1.0 (0.9, 1.3)c 28.420 <  0.001
apoA-1, g/L 1.1 (1.0, 1.3) 1.1 (1.0, 1.3) 1.1 (1.0, 1.3) 1.1 (1.0, 1.3) 5.934 0.115
apo B, g/L 0.7 (0.6, 0.9) 0.7 (0.6, 0.9)a 0.8 (0.6, 0.9)bd 0.8 (0.7, 1.0)cef 319.269 <  0.001
Lipid-lowering medications, n (%) 1063 (25.9) 926 (22.7)a 899 (22.0) 1051 (25.8)ef 27.728 <  0.001
Antiplatelet agents, n (%) 811 (19.8) 776 (19.0) 809 (19.8) 818 (20.0) 1.401 0.705
Anticoagulants, n (%) 1194 (29.1) 962 (23.6)a 861 (21.0)bd 890 (21.8)c 89.187 <  0.001
 NOAC 684 (57.3) 483 (50.2)a 419 (48.7)b 510 (57.3) 24.316 <  0.001
 Warfarin 510 (42.7) 479 (49.8)a 442 (51.3)b 380 (42.7)   
  1. Abbreviations: AF Atrial fibrillation, Lp(a) Lipoprotein(a), HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol, TC Total cholesterol, TG Triglycerides, RDW Red-cell distribution width, apoA-I Apolipoprotein A1, apo B Apolipoprotein B, NOAC New oral anticoagulants
  2. aindicates a significant difference between Q1 and Q2
  3. bindicates a significant difference between Q1 and Q3
  4. cindicates a significant difference between Q1 and Q4
  5. dindicates a significant difference between Q2 and Q3
  6. eindicates a significant difference between Q2 and Q4
  7. findicates a significant difference between Q3 and Q4